Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Mette Yde Hochreuter, Morten Dall, Jonas T. Treebak, Romain Barres
Summary: This review summarizes the current knowledge on liver miRNA profiling studies in patients with different stages of NAFLD. It analyzes the mechanistic role of miRNA species such as miR-34a, miR-122, and miR-21 in NAFLD development and highlights novel NAFLD-related miRNAs. The review also discusses the role of exosomal microRNAs as intercellular or inter-organ messengers in NAFLD and explores the potential of circulating NAFLD-associated miRNAs as minimally invasive tools for diagnosis, staging, and prognosis, as well as their potential as NASH pharmacotherapeutic targets. Finally, the article discusses future research directions in the miRNA field.
MOLECULAR METABOLISM
(2022)
Review
Medicine, General & Internal
Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Summary: New developments in non-invasive assessment methods show potential in diagnosing and monitoring NAFLD. Magnetic resonance imaging and blood biomarkers can be used to detect hepatic steatosis and fibrosis, but further research is needed to confirm their role in treatment monitoring.
CHINESE MEDICAL JOURNAL
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Roberta Catania, Alessandro Furlan, Andrew D. Smith, Jaideep Behari, Mitchell E. Tublin, Amir A. Borhani
Summary: The study found that MRI-derived liver surface nodularity (LSN) score can accurately detect advanced liver fibrosis in NAFLD patients. There is a strong correlation between LSN score and fibrosis stage, with 81% sensitivity and 88% specificity for detecting F3-F4 fibrosis.
EUROPEAN RADIOLOGY
(2021)
Review
Medicine, General & Internal
Yasaman Vali, Jenny Lee, Jerome Boursier, Rene Spijker, Joanne Verheij, M. Julia Brosnan, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad Hadi Zafarmand
Summary: The meta-analysis showed that FibroTest(TM) performed well in detecting cirrhosis but had limited accuracy in detecting significant and advanced fibrosis in NAFLD patients. Further high-quality studies are needed to validate the test's reliability for detecting different fibrosis levels and to compare its performance in different settings.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Ville T. Mannisto, Veikko Salomaa, Martti Farkkila, Antti Jula, Satu Mannisto, Iris Erlund, Jouko Sundvall, Annamari Lundqvist, Markus Perola, Fredrik Aberg
Summary: In Finnish population cohorts of NAFLD, the absolute risk of liver-related outcomes is low, with much higher risks of cardiovascular disease and cancer, emphasizing the need for more individualized and holistic risk-stratification in NAFLD.
LIVER INTERNATIONAL
(2021)
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tracey G. Simon, Bjorn Roelstraete, Naim Alkhouri, Hannes Hagstrom, Johan Sundstrom, Jonas F. Ludvigsson
Summary: This study found that children and young adults with biopsy-proven NAFLD had significantly higher rates of incident MACE, including ischaemic heart disease and congestive heart failure, compared to matched population controls.
Article
Multidisciplinary Sciences
Kawin Tangvoraphonkchai, Tanita Suttichaimongkol, Churairat Kularbkaew, Prakasit Sangaimwibool, Wattana Sukeepaisarnjaroen
Summary: This study evaluates the application of a novel serum marker M2BPGi in fibrosis staging. By comparing the M2BPGi levels among healthy donors and hepatitis C patients, it is found that M2BPGi shows superior performance in distinguishing between liver disease populations and healthy controls.
SCIENTIFIC REPORTS
(2022)
Article
Gastroenterology & Hepatology
Cristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, Guido Baselli, Paola Dongiovanni, Irene Zanoni, Luigi Santoro, Silvia Maier, Antonio Liguori, Marica Meroni, Vittorio Borroni, Roberta D'Ambrosio, Rocco Spagnuolo, Anna Alisi, Alessandro Federico, Elisabetta Bugianesi, Salvatore Petta, Luca Miele, Umberto Vespasiani-Gentilucci, Quentin M. Anstee, Felix Stickel, Jochen Hampe, Janett Fischer, Thomas Berg, Anna Ludovica Fracanzani, Giorgio Soardo, Helen Reeves, Daniele Prati, Stefano Romeo, Luca Valenti
Summary: This study utilized polygenic risk scores (PRS) to investigate the causal relationship between hepatic fat and HCC, improving the accuracy of HCC detection and helping to stratify HCC risk in individuals with dysmetabolism. The PRS showed robust predictions for HCC in both high-risk individuals and the general population.
JOURNAL OF HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Angela Rojas, Maria Rosario Garcia-Lozano, Antonio Gil-Gomez, Manuel Romero-Gomez, Javier Ampuero
Summary: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, and its development is closely linked to obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. The cause of NAFLD-linked fibrosis progression is still unclear, posing challenges for the development of new therapies. Cirrhosis is associated with the activation of hepatic stellate cells (HSC) and excess accumulation of extracellular matrix proteins. Oxidative stress and glutaminolysis are potential antifibrotic targets. This review focuses on the role of the glutaminolysis-ammonia-urea cycle axis in NAFLD progression and suggests it as a novel therapeutic target.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Review
Cell Biology
Yicheng Zhou, Zhangwang Li, Minxuan Xu, Deju Zhang, Jitao Ling, Peng Yu, Yunfeng Shen
Summary: This review discusses the crucial role of O-GlcNAcylation in the development of NAFLD, explores the impact of therapeutic approaches on O-GlcNAcylation, and presents novel insights into the pathogenesis and treatments of NAFLD.
Review
Immunology
Bader Alabdulaali, Fatema Al-rashed, Mohammed Al-Onaizi, Anwar Kandari, Joanna Razafiarison, Dorothy Tonui, Michayla R. Williams, Camille Bleriot, Rasheed Ahmad, Fawaz Alzaid
Summary: The liver is responsible for metabolizing and detoxifying blood, and consists of different cell types, including macrophages. These macrophages can be either resident Kupffer cells or differentiated from circulating monocytes. They play a role in maintaining liver homeostasis and can also contribute to disease progression. In non-alcoholic fatty liver disease (NAFLD), abnormal function of these macrophages leads to the development of liver conditions. Targeting these macrophages has become a potential therapeutic strategy for NAFLD.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Sebastian J. Wallace, Frank Tacke, Robert F. Schwabe, Neil C. Henderson
Summary: Non-alcoholic fatty liver disease is becoming an epidemic, with non-alcoholic steatohepatitis as the leading cause of liver transplantation. Liver fibrosis is a key factor in the prognosis of NAFLD/NASH, and understanding the cellular interactome can lead to the development of new therapies.
Article
Hematology
Osamu Kurihara, Fumitaka Okajima, Masamichi Takano, Katsuhito Kato, Ryo Munakata, Daisuke Murakami, Yasushi Miyauchi, Naoya Emoto, Hitoshi Sugihara, Yoshihiko Seino, Wataru Shimizu
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2018)
Meeting Abstract
Peripheral Vascular Disease
Fumitaka Okajima, Osamu Kurihara, Masamichi Takano, Hitoshi Sugihara, Naoya Emoto
ATHEROSCLEROSIS SUPPLEMENTS
(2018)
Article
Endocrinology & Metabolism
Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto
Article
Endocrinology & Metabolism
Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto
Article
Gastroenterology & Hepatology
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Mai Koeda, Yuji Yoshida, Tomomi Okubo, Ai Nakagawa, Norio Itokawa, Chisa Kondo, Katsuhisa Nakatsuka, Takushi Masu, Keizo Kato, Noritomo Shimada, Tsutomu Hatori, Naoya Emoto, Masayoshi Kage, Katsuhiko Iwakiri
DIGESTIVE AND LIVER DISEASE
(2019)
Article
Multidisciplinary Sciences
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadamichi Kawano, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Chiaki Kawamoto, Tsutomu Hatori, Naoya Emoto, Etsuko Iio, Yasuhito Tanake, Katsuhiko Iwakiri
Article
Endocrinology & Metabolism
Hiroshi Yamada, Fumitaka Okajima, Takeshi Onda, Shunji Fujimori, Naoya Emoto, Hitoshi Sugihara
BMC ENDOCRINE DISORDERS
(2020)
Article
Endocrinology & Metabolism
Naoya Emoto, Akimi Soga, Izumi Fukuda, Kyoko Tanimura-Inagaki, Taro Harada, Hajime M. Koyano, Rei Goto, Hitoshi Sugihara
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2020)
Article
Medicine, General & Internal
Fumitaka Okajima, Hitoshi Sugihara, Naoya Emoto
Summary: The study found that adding alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia in patients with type 2 diabetes.
JOURNAL OF NIPPON MEDICAL SCHOOL
(2021)
Article
Medicine, General & Internal
Naoya Emoto, Mikiko Okazaki-Hada, Yuji Yamaguchi, Fumitaka Okajima, Rei Goto, Hitoshi Sugihara
Summary: The study found that risk preferences of patients with thyrotoxicosis remain relatively stable in hyperthyroid and euthyroid states, but willingness to pay for medical costs may change after normalization of thyroid function.
PATIENT PREFERENCE AND ADHERENCE
(2021)
Article
Multidisciplinary Sciences
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Summary: This study found that the severity of fibrosis in NAFLD is significantly and independently associated with high-risk CIMT. Non-invasive liver fibrosis markers and scoring systems may help estimate the risk of atherosclerosis progression in patients with NAFLD.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Kazuhiko Horiguchi, Yusaku Yoshida, Kenji Iwaku, Naoya Emoto, Toshihiko Kasahara, Junichiro Sato, Hiroki Shimura, Hisakazu Shindo, Satoru Suzuki, Hidekazu Nagano, Fumihiko Furuya, Noriko Makita, Fumihiko Matsumoto, Katsunori Manaka, Norisato Mitsutake, Megumi Miyakawa, Susumu Yokoya, Iwao Sugitani
Summary: Studies suggest that active surveillance is a safe and effective strategy for low-risk papillary thyroid microcarcinomas, preserving quality of life and reducing medical costs. However, high-risk cases should be closely monitored and surgery performed promptly during active surveillance.
Article
Endocrinology & Metabolism
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Summary: The study demonstrated that SGLT2-Is therapy can significantly improve liver inflammation, fatty changes, and fibrosis in patients with NAFLD, indicating their potential superiority to other oral hypoglycemic agents in addressing these conditions.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2021)
Article
Endocrinology & Metabolism
Tomoko Nagamine, Jaeduk Yoshimura Noh, Naoya Emoto, Takahito Kogai, Akira Hishinuma, Fumitaka Okajima, Hitoshi Sugihara